Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) disclosed a Next Day Disclosure Return on 16 September 2026 detailing a fresh share repurchase executed on the Hong Kong Stock Exchange.

Key transaction • Date of repurchase: 16 September 2026 • Volume: 205,200 H-shares, acquired for treasury holding • Price range: HKD 5.465–5.500 per share • Aggregate consideration: HKD 1.13 million • Percentage of issued H-shares (pre-transaction): 0.09 %

Capital structure post-transaction (16 September 2026) • Issued shares (excluding treasury): 240.06 million • Treasury shares: 5.34 million • Total issued shares unchanged: 245.40 million

Repurchase mandate utilisation • General mandate authorised on 15 June 2026: up to 24.15 million shares • Cumulative repurchases under the mandate: 1.46 million shares • Utilisation ratio: 0.60 % of issued shares outstanding on mandate date

Moratorium on new issuance Under Main Board Rule 10.06(3)(a), Jiuyuan Gene is restricted from issuing, selling or transferring shares from treasury until 16 October 2026 (30 days post-repurchase).

Regulatory compliance The board confirmed that the transaction adhered to Hong Kong Listing Rules and all relevant legal and regulatory requirements, with funds for the repurchase fully settled.